Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Octoplus publishes first quarter business update

Abstract:
OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), the drug delivery company, publishes a business update for the first quarter of 2010 today.

Octoplus publishes first quarter business update

Leiden, the Netherlands | Posted on May 19th, 2010

Highlights

Successful development of LocteronŽ

* Locteron Phase IIb data presented at EASL demonstrates that Locteron dosed every other week consistently achieves a reduction in flu-like side effects while maintaining antiviral efficacy comparable to the weekly dosed standard of care, providing compelling proof that Locteron offers a significant improvement in interferon therapy
* Positive Phase IIb data on Locteron further validates the clinical benefit of OctoPlus' PolyActiveŽ drug delivery technology
* Locteron's Phase IIb study expected to be successfully completed in 2010

Advancing and broadening product pipeline

* Advancing our pipeline of a number of products incorporating OctoPlus' PolyActive drug delivery technology on behalf of major biotech and pharmaceutical companies
* Expecting to significantly broaden our product pipeline in the coming year, as our drug delivery expertise has been validated by the positive results of Locteron

Q1 Financials

* Revenues coming from drug delivery programs and services (excluding Locteron) at the same level as the same period last year
* Revenues coming from Locteron in line with our expectations but substantially lower than the same period last year as development and manufacturing for phase IIb is completed
* Our expertise and knowledge from microsphere development and clinical manufacturing attracts significant interest from multiple companies, resulting in a stronger and broader acquisition pipeline of new projects than at any time in the company's history
* Strong reduction in costs achieved compared with same period last year following the successful completion of the efficiency measures announced in September 2009

Simon Sturge, CEO of OctoPlus comments: "I am encouraged by the growing adoption by the biotech and pharmaceutical industries of OctoPlus' PolyActiveŽ technology which is a continued endorsement of our strategy. The positive results of LocteronŽ show the broad potential of our drug delivery technology. Although the environment remains volatile, the progress in the first quarter is encouraging."

For further information, please contact: Rianne Roukema, Corporate Communications: telephone number +31 (71) 524 1071, or send an e-mail to Investor Relations at

This document may contain certain forward-looking statements relating to the business, financial performance and results of OctoPlus and the industry in which it operates. These statements are based on OctoPlus' current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words "expect", "anticipate", "predict", "estimate", "project", "plan", "may", "should", "would", "will", "intend", "believe" and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.

####

About Octoplus
OctoPlus is a drug delivery service company committed to the creation of improved pharmaceutical products that are based on OctoPlus' proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. OctoPlus focuses on the development of long-acting, controlled release versions of known protein therapeutics, other drugs, and vaccines on behalf of its clients.

The clinically most advanced product incorporating our technology is Biolex Therapeutics' lead product LocteronŽ, a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C. OctoPlus licensed Locteron exclusively to Biolex in October 2008. Locteron is being manufactured for Biolex by OctoPlus and is currently in Phase IIb clinical studies.

In addition, OctoPlus is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients.

OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbol OCTO. For more information about OctoPlus, please visit our website www.octoplus.nl.

For more information, please click here

Contacts:
Rianne Roukema
Corporate Communications
telephone number +31 (71) 524 1071

Investor Relations

Copyright © Octoplus

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Nano Ruffles in Brain Matter: Freiburg researchers decipher the role of nanostructures around brain cells in central nervous system function October 31st, 2014

Gold nanoparticle chains confine light to the nanoscale October 31st, 2014

'Nanomotor lithography' answers call for affordable, simpler device manufacturing October 31st, 2014

Device invented at Johns Hopkins provides up-close look at cancer on the move: Microscopic view of metastasis could give insight about how to keep cancer in check October 31st, 2014

Nanomedicine

Nano Ruffles in Brain Matter: Freiburg researchers decipher the role of nanostructures around brain cells in central nervous system function October 31st, 2014

Production of Biocompatible Polymers in Iran October 30th, 2014

Amorphous Coordination Polymer Particles as alternative to classical nanoplatforms for nanomedicine October 30th, 2014

'Electronic skin' could improve early breast cancer detection October 29th, 2014

Announcements

Nano Ruffles in Brain Matter: Freiburg researchers decipher the role of nanostructures around brain cells in central nervous system function October 31st, 2014

Gold nanoparticle chains confine light to the nanoscale October 31st, 2014

'Nanomotor lithography' answers call for affordable, simpler device manufacturing October 31st, 2014

Device invented at Johns Hopkins provides up-close look at cancer on the move: Microscopic view of metastasis could give insight about how to keep cancer in check October 31st, 2014

Financial Reports

Aspen Aerogels, Inc. Schedules Third Quarter 2014 Earnings Release and Conference Call for November 6, 2014 October 17th, 2014

Nanometrics to Announce Third Quarter Financial Results on October 28, 2014 October 8th, 2014

Harris & Harris Group Letter to Shareholders on Website August 19th, 2014

Arrowhead Reports Fiscal 2014 Third Quarter Financial Results and Provides Update on ARC-520 August 12th, 2014

Nanobiotechnology

Tiny carbon nanotube pores make big impact October 29th, 2014

Molecular beacons shine light on how cells 'crawl' October 27th, 2014

Breakthrough in molecular electronics paves the way for DNA-based computer circuits in the future: DNA-based programmable circuits could be more sophisticated, cheaper and simpler to make October 27th, 2014

NYU Researchers Break Nano Barrier to Engineer the First Protein Microfiber October 23rd, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE